Evidence map›Paper›PMID 42402086›Full record

ReviewDiscover nano2026

Recent advances in metal-organic frameworks for the diagnosis and treatment of breast cancer.

Sanket N Fulkari, Mujibullah Sheikh, Manish P Deshmukh, Rajat Mahajan, Tejas Pimple, Isha Mirzapure

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sanket N FulkariDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DMIHER) (Deemed to Be University, DU), Wardha, Maharashtra, 442001, India.
Mujibullah SheikhDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DMIHER) (Deemed to Be University, DU), Wardha, Maharashtra, 442001, India. mujib123sheikh@gmail.com.
Manish P DeshmukhDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DMIHER) (Deemed to Be University, DU), Wardha, Maharashtra, 442001, India. manishpdeshmukh@gmail.com.
Rajat MahajanDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DMIHER) (Deemed to Be University, DU), Wardha, Maharashtra, 442001, India.
Tejas PimpleDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DMIHER) (Deemed to Be University, DU), Wardha, Maharashtra, 442001, India.
Isha MirzapureDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DMIHER) (Deemed to Be University, DU), Wardha, Maharashtra, 442001, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains the most prevalent malignancy among women worldwide, presenting significant clinical challenges due to tumor heterogeneity, multidrug resistance (MDR), and the severe systemic toxicity associated with conventional chemotherapy. In the rapidly evolving field of nanomedicine, Metal-Organic Frameworks (MOFs) have emerged as a superior class of porous nanomaterials with exceptional potential for oncology applications. Distinguished by their ultra-high surface area, tunable porosity, and biodegradable nature, MOFs offer a versatile platform for encapsulating chemotherapeutic agents, genetic materials, and photosensitizers. This review provides a comprehensive overview of the recent advancements in MOF-based nanoplatforms for the diagnosis and treatment of breast cancer. We critically analyze the synthesis and functionalization strategies that enhance the stability and targeting capability of MOFs in the physiological environment. Furthermore, we highlight the development of stimuli-responsive drug delivery systems that utilize the unique tumor microenvironment (pH, redox, and ATP) for controlled release. Finally, the review discusses the dual role of MOFs as theranostic agents integrating bioimaging (MRI, CT, and optical imaging) with therapeutic modalities (chemotherapy, photothermal, and photodynamic therapy) and outlines the future perspectives for their clinical translation.

Indexed as

Breast cancerMetal–organic frameworks (MOFs)NanomedicineNanoparticlesTargeted drug deliveryTheranostics

Identifiers

PMID42402086
PMCPMC13333585

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.